DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION

The present invention relates to compositions and methods for treating and/or preventing heart failure with preserved ejection fraction (HFpEF), especially in subjects with an impaired NO-cGMP-PKG signalling axis. The inventors established that not all patients with clinically defined HFpEF suffer from insufficient NO-cGMP- PKG signalling. In accordance with the invention, patients with an HFpEF diagnosis can be selected/stratified based on biomarkers such as NADPH oxidase Type 5 (Nox5) plasma levels, nitration of tyrosine residues on plasma proteins and/or cell- based assays. Moreover, the inventors have found that treating this signalling network at two or more nodes, especially sGC and NO synthase, achieves the first-in-class mechanism-based, causal and high precision therapy for HFpEF endotype which is defined by insufficient NO-cGMP-PKG signalling..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 26. Okt. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

SCHMIDT HARALD HORST HEINZ WILHELM [VerfasserIn]
CALVO CRISTIAN NOGALES [VerfasserIn]
PETRAINA ALEXANDRA [VerfasserIn]
KNÖPP KAI [VerfasserIn]
MUCKE HERMANN ALOIS MARTIN [VerfasserIn]
SEDDING DANIEL GERHARD FRANZISKUS [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che
G01N: Investigating or analysing materials by determining (...)
tec

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-10-26, Last update posted on www.tib.eu: 2023-11-17, Last updated: 2023-11-24

Patentnummer:

WO2023204698

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA018406742